WS
ZYNE

Wedbush Securities’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Wedbush Securities’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,900
Closed -$39K – 1010
2020
Q3 		$39K Buy
+11,900
New +$43.7K ﹤0.01% 900

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wedbush Securities's ZYNE Position: Q4 2020 in Review

Wedbush Securities sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2020, closing a stake of 11,900 shares — an estimated $39K sold.

Wedbush Securities first reported a position in ZYNE in Q3 2020 and held it in 1 quarter. The position peaked at $39K in Q3 2020. 58 funds tracked by Wall St. Rank hold ZYNE as of Q4 2020.

  • Wedbush Securities reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 11,900 Zynerba Pharmaceuticals, Inc shares in Q4 2020, an estimated $39K.
  • Wedbush Securities first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Zynerba Pharmaceuticals, Inc position peaked at $39K in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.